Vycellix Platform: VY-UC
Redefining Allogeneic Cell-based Therapeutics & Beyond
The prospect of administering donor-based cells, tissues or organs without the risk of immune rejection or the need for toxic immunosuppressive drugs is the “Holy Grail” of transplantation; VY-UC represents such a breakthrough. The major immunological hurdle to the transplantation of allogeneic cells/tissues is the expression of MHC molecules, also known as human leukocyte antigens (HLA). Cells modified by VY-UC avoid immune recognition of grafted cells without impacting HLA while conserving viability, functionality and persistence.
